(VIANEWS) – WALLENIUS WILHELMS (WAWI.OL), BOUVET (BOUV.OL), SPAREBANKEN ØST (SPOG.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. WALLENIUS WILHELMS (WAWI.OL)
1027.3% sales growth and 30.36% return on equity
Wallenius Wilhelmsen ASA, together with its subsidiaries, engages in the logistics and transportation business worldwide. It operates through three segments: Shipping Services, Logistics Services, and Government Services. The company provides liner services through a fleet of modern and versatile RoRo vessels, which carry a mix of products, such as auto, construction, mining, agriculture machinery, and breakbulk products. In addition, it offers inland transportation services, as well as operates vehicle and equipment processing centers and inland distribution networks. The company serves agriculture, automotive, aviation, boats and yachts, breakbulk, commercial vehicles, construction, machinery and machine tools, mining, oil and gas, power and energy, and rail industries. It operates approximately 125 vessels servicing 15 trade routes, 66 processing centers, and 8 marine terminals. Wallenius Wilhelmsen ASA was founded in 1861 and is based in Lysaker, Norway.
Earnings Per Share
As for profitability, WALLENIUS WILHELMS has a trailing twelve months EPS of kr21.53.
PE Ratio
WALLENIUS WILHELMS has a trailing twelve months price to earnings ratio of 5.95. Meaning, the purchaser of the share is investing kr5.95 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.36%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.4%, now sitting on 5.21B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 795.7% and 854.3%, respectively.
Moving Average
WALLENIUS WILHELMS’s worth is way above its 50-day moving average of kr107.43 and way higher than its 200-day moving average of kr102.66.
Volume
Today’s last reported volume for WALLENIUS WILHELMS is 461741 which is 6.84% below its average volume of 495644.
More news about WALLENIUS WILHELMS.
2. BOUVET (BOUV.OL)
9.7% sales growth and 60.9% return on equity
Bouvet ASA provides IT and digital communication consultancy services for public and private sector companies in Norway, Sweden, and internationally. The company was incorporated in 1995 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, BOUVET has a trailing twelve months EPS of kr3.48.
PE Ratio
BOUVET has a trailing twelve months price to earnings ratio of 19.94. Meaning, the purchaser of the share is investing kr19.94 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.5%, now sitting on 3.22B for the twelve trailing months.
More news about BOUVET.
3. SPAREBANKEN ØST (SPOG.OL)
9.6% sales growth and 10.7% return on equity
Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; current accounts; home mortgage loans; and mortgage loans for new and used cars. It also provides vehicles, houses and contents, boats, and leisure insurance products, as well as life and health insurance products; and shares and funds trading services. In addition, the company buys, sells, and stores cryptocurrencies, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.
Earnings Per Share
As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr8.07.
PE Ratio
SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 7.24. Meaning, the purchaser of the share is investing kr7.24 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.7%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Mar 22, 2024, the estimated forward annual dividend rate is 5.4 and the estimated forward annual dividend yield is 9.36%.
Moving Average
SPAREBANKEN ØST’s value is higher than its 50-day moving average of kr57.89 and higher than its 200-day moving average of kr54.53.
More news about SPAREBANKEN ØST.
4. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
More news about SANOFI.
